Profile data is unavailable for this security.
About the company
Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.
- Revenue in AUD (TTM)11.17m
- Net income in AUD-109.34m
- Incorporated2004
- Employees83.00
- LocationMesoblast LtdL 38 55 Collins StMELBOURNE 3000AustraliaAUS
- Phone+61 39639-6036
- Fax+61 39639-6030
- Websitehttps://www.mesoblast.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dimerix Ltd | 181.28k | -10.87m | 288.86m | 0.00 | -- | 130.32 | -- | 1,593.46 | -0.0294 | -0.0294 | 0.0005 | 0.004 | 0.0169 | -- | 0.7586 | -- | -101.36 | -70.77 | -128.88 | -110.81 | -- | -- | -5,994.52 | -61,882.73 | -- | -- | 0.4541 | -- | 1,452.32 | 12.76 | -31.57 | -- | -8.26 | -- |
| Race Oncology Ltd | 885.59k | -11.17m | 316.85m | -- | -- | 14.88 | -- | 357.78 | -0.069 | -0.069 | 0.0055 | 0.125 | 0.0336 | -- | 0.326 | -- | -42.44 | -43.50 | -43.67 | -45.25 | -- | -- | -1,261.86 | -5,058.82 | -- | -- | 0.00 | -- | 997.63 | 93.78 | 11.41 | -- | -- | -- |
| Imugene Ltd | 0.00 | -89.24m | 411.56m | 0.00 | -- | 2.06 | -- | -- | -0.0132 | -0.0132 | 0.00 | 0.0272 | 0.00 | -- | -- | -- | -40.29 | -26.64 | -43.53 | -28.00 | -- | -- | -- | -- | -- | -- | 0.021 | -- | -- | -- | -0.1207 | -- | -- | -- |
| Immutep Ltd | 256.62k | -40.50m | 421.26m | 19.00 | -- | 3.01 | -- | 1,641.56 | -0.039 | -0.039 | 0.0002 | 0.0964 | 0.0025 | -- | 2.48 | -- | -38.61 | -36.31 | -41.57 | -39.21 | -- | -- | -15,782.59 | -919.13 | -- | -- | 0.0138 | -- | -24.64 | -51.34 | -23.86 | -- | 47.40 | -- |
| Opthea Ltd | 175.25k | -241.86m | 470.97m | 5.00 | -- | -- | -- | 2,687.44 | -0.427 | -0.427 | 0.0003 | -0.0976 | 0.0007 | -- | 0.1772 | -- | -100.84 | -90.04 | -116.05 | -100.93 | -99.74 | -197.19 | -138,008.10 | -69,641.71 | -- | -29.64 | 1.35 | -- | 19.55 | -34.31 | -53.55 | -- | -3.82 | -- |
| PYC Therapeutics Ltd | 21.54m | -21.65m | 536.60m | 23.00 | -- | 14.36 | -- | 24.91 | -0.006 | -0.006 | 0.0062 | 0.008 | 0.6034 | -- | 2.48 | -- | -60.70 | -41.67 | -81.23 | -46.95 | -- | -- | -100.60 | -178.69 | -- | -50.32 | 0.0174 | -- | -1.11 | 218.52 | -64.39 | -- | 18.46 | -- |
| Mesoblast Ltd | 11.17m | -109.34m | 1.27bn | 83.00 | -- | 1.48 | -- | 113.31 | -0.1325 | -0.1325 | 0.0136 | 0.7502 | 0.0112 | -- | 3.71 | 134,618.30 | -10.92 | -12.66 | -11.67 | -13.92 | -190.91 | -78.09 | -978.54 | -593.91 | -- | -3.01 | 0.1934 | -- | -26.56 | -15.43 | 10.35 | -- | 5.60 | -- |
| Clarity Pharmaceuticals Ltd | 0.00 | -30.56m | 1.90bn | -- | -- | 30.29 | -- | -- | -0.1167 | -0.1167 | 0.00 | 0.2017 | 0.00 | -- | -- | -- | -41.34 | -- | -45.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.57 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Jul 2024 | 36.43m | 3.19% |
| M&G Investment Management Ltd.as of 31 Aug 2023 | 27.50m | 2.41% |
| Thorney Investment Group Australia Pty Ltd.as of 22 Sep 2023 | 21.09m | 1.85% |
| Vanguard Investments Australia Ltd.as of 30 Jun 2024 | 13.43m | 1.18% |
| Independent Asset Management Pty Ltd.as of 22 Sep 2023 | 8.00m | 0.70% |
| Dimensional Fund Advisors LPas of 31 May 2024 | 5.22m | 0.46% |
| DFA Australia Ltd.as of 31 May 2024 | 4.78m | 0.42% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 2.76m | 0.24% |
| BlackRock Asset Management North Asia Ltd.as of 30 Apr 2024 | 2.62m | 0.23% |
| Charles Schwab Investment Management, Inc.as of 03 Jul 2024 | 2.03m | 0.18% |
